Asthma

Novartis forms COPD alliance

Novartis forms COPD alliance

Novartis has announced the formation of an alliance between Vectura
Group and Arakis to develop and commercialise AD 237, a novel, long
acting, antimuscarinic agent, for the treatment of chronic
obstructive pulmonary disease (COPD).

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All